Twist Bioscience Corp. Hits New 52-Week High of $104.45

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 104.45 on July 1, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 2,730 million. Over the past year, Twist Bioscience Corp. has demonstrated impressive growth, with a remarkable 104.46% increase in its stock price, significantly outperforming the S&P 500, which recorded a 20.74% gain during the same period. Despite being a loss-making company, the stock's performance reflects a robust market position within its industry. Key financial metrics reveal a price-to-book ratio of 5.99, indicating the market's valuation of the company's assets. Additionally, the company's debt-to-equity ratio stands at -0.41, suggesting a unique capital structure. However, it is important to note that the company does not currently offer a dividend yield. As Twist Bioscience Corp. continues to navigate the competitive landscape, this new high marks a noteworthy point in its financial journey.